System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Publications

Journal Article Epublish

PubMed: 42756981 DOI: 10.4103/sjopt.sjopt_99_26

Real-world outcomes of faricimab in treatment-naïve diabetic macular edema: The Middle East perspective.

Saudi J Ophthalmol 40(3):234-241

Authors: Abdulrahman F AlBloushi, Ahmed M Bedda, Ahmed Habib, Anant Pai, Ahmed Souka, Faisal Alkathery, Yasmine Bedda, Eman Samir, Heba Abdelaziz, Hashem A Abu Serhan

Affiliations

  • Department of Ophthalmology, College of Medicine, King Saud University, Riyadh, Saudi Arabia.
  • Department of Ophthalmology, Faculty of Medicine, Alexandria University, Alexandria, Egypt.
  • Department of Ophthalmology, Ain Shams University, Cairo, Egypt. Al Mashreq Eye Center, Cairo, Egypt.
  • Department of Ophthalmology, Hamad Medical Corporation, Doha, Qatar.
  • iCare Eye Center, Alexandria, Egypt.
  • Al Mashreq Eye Center, Cairo, Egypt.

Abstract

PURPOSE

Diabetic macular edema (DME) is a major cause of visual impairment in patients with diabetic retinopathy. While intravitreal anti-vascular endothelial growth factor (anti-VEGF) monotherapy has been considered standard of care, many patients have suboptimal treatment responses. Faricimab, which targets angiopoietin-2 and VEGF-A, has shown efficacy and tolerability in randomized controlled trials (RCTs). As RCT results are often challenging to replicate in real-world practice, this study assessed the impact of faricimab on DME outcomes in Middle Eastern real-world settings.

METHODS

Treatment-naïve patients with DME receiving faricimab between 2023 and 2025 with ≥6 months follow-up were examined at five sites in Egypt, Saudi Arabia, and Qatar. Following loading doses, patients were treated with either pro re nata or treat-and-extend regimens. Outcomes included visual acuity (VA), retinal thickness, number of injections, and adverse events (AEs). Data were analyzed separately by site.

RESULTS

Eighty-eight eyes were treated across sites, with mean follow-up ranging from 7.6 to 12.5 months. Mean number of faricimab injections ranged from 3.0 to 4.2. Improvements from baseline in VA (mean logarithm of the Minimal Angle of Resolution reductions between -0.16 and -0.49) and retinal thickness (mean reductions between -50.6 μm and -194.0 μm) were observed with faricimab treatment at all sites, regardless of differences in treatment protocol or observation time points. No AEs of intra-ocular inflammation or endophthalmitis were observed.

CONCLUSION

The findings suggest faricimab conferred visual and anatomical improvements in a heterogeneous group of patients with DME in real-world Middle East settings. Further real-world studies are essential to confirm long-term safety and effectiveness in clinical practice.

MeSH

Injections, Vascular Endothelial Growth Factor A, Macular Edema, Intravitreal Injections, Therapeutics, Retinaldehyde, Edema